Sophia Genetics closed its previously announced underwritten public offering after strong investor demand, selling 12,104,900 ordinary shares at $4.75 per share for total gross proceeds of $57.5 million. The offering was oversubscribed and underwriters fully exercised an option to purchase an additional 1,578,900 shares. The company said it will use proceeds for working capital and general corporate purposes, including R&D, with a focus on expanding features, applications, and data modalities for the Sophia DDM platform. The remainder supports sales and marketing efforts. The deal highlights continued capital access for genomic-diagnostics companies, particularly those expanding data modalities and clinical decision-support capabilities.